19,597 Shares in Vera Therapeutics, Inc. $VERA Acquired by Fox Run Management L.L.C.

Key Points

• Fox Run Management L.L.C. has acquired 19,597 shares of Vera Therapeutics, Inc., valued at approximately $471,000, as indicated in their recent SEC filing.
• Insider Patrick G. Enright purchased 40,607 shares of Vera Therapeutics at an average price of $22.35, totaling around $907,566, increasing his ownership by 1.14%.
• Vera Therapeutics reported a loss of ($1.20) EPS in its latest earnings, missing consensus estimates, with analysts projecting an average of -2.89 EPS for the current year.

Fox Run Management L.L.C. purchased a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 19,597 shares of the company's stock, valued at approximately $471,000.

Other institutional investors and hedge funds have also modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in Vera Therapeutics during the fourth quarter worth about $56,000. Summit Investment Advisors Inc. raised its position in Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after acquiring an additional 639 shares during the last quarter. GAMMA Investing LLC raised its position in Vera Therapeutics by 1,779.1% during the first quarter. GAMMA Investing LLC now owns 8,287 shares of the company's stock worth $199,000 after acquiring an additional 7,846 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Vera Therapeutics by 19.7% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,533 shares of the company's stock worth $229,000 after acquiring an additional 1,572 shares during the last quarter. Finally, Knott David M Jr acquired a new position in Vera Therapeutics during the first quarter worth about $240,000. Institutional investors and hedge funds own 99.21% of the company's stock.

Insider Transactions at Vera Therapeutics

In related news, Director Patrick G. Enright bought 40,607 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average cost of $22.35 per share, for a total transaction of $907,566.45. Following the completion of the acquisition, the director owned 3,596,593 shares in the company, valued at $80,383,853.55. This trade represents a 1.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 16.30% of the company's stock.

Wall Street Analysts Forecast Growth

VERA has been the subject of a number of research reports. Guggenheim restated a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. HC Wainwright restated a "buy" rating and set a $85.00 target price (up previously from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. Cantor Fitzgerald lowered their price target on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Finally, Wolfe Research reiterated a "peer perform" rating on shares of Vera Therapeutics in a report on Monday, August 4th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $63.00.

Vera Therapeutics Stock Performance

Shares of NASDAQ VERA opened at $21.80 on Tuesday. The company has a market cap of $1.39 billion, a PE ratio of -6.09 and a beta of 1.17. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03. The company has a 50-day simple moving average of $22.12 and a 200-day simple moving average of $24.39.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same quarter in the previous year, the firm posted ($0.62) EPS. On average, equities analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.